Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) traded at $112.94 at last check on Tuesday, January 24, made an upward move of 0.12% on its previous day’s price.
Looking at the stock we see that its previous close was $112.81 and the beta (5Y monthly) reads 1.18 with the day’s price range being $112.81 – $113.11. The company has a trailing 12-month PE ratio of 46.39. In terms of its 52-week price range, HZNP has a high of $117.49 and a low of $57.84. The company’s stock has lost about -0.19% over that past 30 days.
Horizon Therapeutics Public Limited Company has a market cap of $25.61 billion and is expected to release its quarterly earnings report on Mar 01, 2023 – Mar 08, 2023. Estimates by analysts give the company expected earnings per share (EPS) of $1.09, with the EPS growth for the year raised at $4.75 for 2022 and $5.41 for next year. These figures represent 2.80% and 13.90% growth in EPS for the two years respectively.
Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $922.92 million, with a low of $912.75 million and a high of $935 million. The median projection represents growth adding up to -9.00% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2022 is expected to hit $3.61 billion, or 11.70% up from figures reported last year.
There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the HZNP stock, short term indicators assign the stock an average of 50% Buy, while medium term indicators assign it an average of 100% Buy. Long term indicators on average place the stock in the category of 50% Buy.
Based on estimates by 10 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 8 have rated the Horizon Therapeutics Public Limited Company (HZNP) stock as a Hold, while 2 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Hold and investors could take advantage and scoop up stock of the company.
Looking further, we note that the PEG ratio for the HZNP stock currently stands at 3.87, and the most recent price level today is -0.23% off its SMA20 and 12.27% from its 50-day simple moving average. The RSI (14) is pointing at 73.31 while the volatility over the past week is 0.21% and jumps to 0.26% over the past one month. The beta value is 1.18, while the average true range (ATR) is currently pointing at 0.88. The average price target for the stock over the next 12 months is $115.50, with the estimates having a low of $74.00 and a high of $140.00. These price ends are 34.48% and -23.96% off the today’s price level respectively, although investors could be excited at the prospect of a -3.15% if the HZNP share price touches on the median price of $116.50.
Let’s briefly compare Horizon Therapeutics Public Limited Company (HZNP) stock to its peers. We find that today’s price change of 0.12% and 30.31% over the past 12 months for HZNP competes that of Pfizer Inc. (PFE), which has seen its stock price fall -1.65% in the latest trading session and is -16.78% over the last one year. Another of its peers GSK plc (GSK) has dropped -2.11% today, and was -22.61% down over the past year. Horizon Therapeutics Public Limited Company has a P/E ratio of 46.39 compared to Pfizer Inc.’s 8.53 and GSK plc’s 14.39. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at -0.40% and -0.23%, respectively, in early deals.
Coming back to Horizon Therapeutics Public Limited Company (NASDAQ:HZNP), we note that the average 3-month trading volume was 4.08 million, while that of the preceding 10-day period stands at 2.71 million. Current shares outstanding are 230.33 million.
The insiders hold 2.62% of the company’s shares while institutions hold 95.80%. The data shows that short shares as of Dec 29, 2022, stood at 6.22 million at a short ratio of 0.97. This represents a 2.74% short interest in shares outstanding on Dec 29, 2022. Shares short fall in December from the previous month at 6.49 million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -0.87% down in year-to-date price movement.